TCR2 Therapeutics is a clinical-stage immunotherapy company developing T cell therapies for patients suffering from cancer by overcoming the limitations of chimeric antigen receptor T cell therapies and engineered T cell therapies that use the full T cell receptor (TCR-T cells). Co.'s TCR Fusion Construct T cells recognize and kill cancer cells by using the entire T cell receptor TCR signaling complex. Co. has clinical trial for TC-210 to treat patients with non-small cell lung cancer, ovarian cancer, malignant pleural/peritoneal mesothelioma and cholangiocarcinoma, and for TC-110 to treat patients with adult acute lymphoblastic leukemia and with aggressive or indolent non-Hodgkin lymphoma. The TCRR stock yearly return is shown above.
The yearly return on the TCRR stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2020 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the TCRR annual return calculation with any dividends reinvested as applicable (on ex-dates).
|